Sunitinib Accord Եվրոպական Միություն - իսպաներեն - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agentes antineoplásicos - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

SUNITINIB 50 mg Կուբա - իսպաներեն - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

sunitinib 50 mg

lotus pharmaceuticals co. ltd - sunitinib (eq. a 66,8 mg de malato de sunitinib) - cápsula - 50 mg

SUNITINIB 125 mg Կուբա - իսպաներեն - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

sunitinib 125 mg

lotus pharmaceuticals co. ltd - sunitinib (eq. a 16,7 mg de malato de sunitinib) - cápsula - 12,5 mg

SUNITINIB 25 mg Կուբա - իսպաներեն - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

sunitinib 25 mg

lotus pharmaceuticals co. ltd - sunitinib (eq. a 33,4 mg de malato de sunitinib) - cápsula - 25 mg